News Summary: Regulators want more on Novo drugs Associated Press Copyright 2013 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Published 10:26 am, Monday, February 11, 2013 Danish drugmaker Novo Nordisk said that U.S. regulators need to see data from a new study that evaluates cardiovascular health before they can finish reviewing the diabetes treatments Tresiba and Ryzodeg for approval. Tresiba and Ryzodeg both use the long-acting insulin degludec, which can help diabetics control their blood sugar levels beyond the 24-hour period offered by current products on the market.